ALM 27134
Alternative Names: ALM-27134; Anti-human IL1RAP antagonist mAb; Anti-IL-1RAP mAb - Almirall S.A; ISB-880; LAD-191Latest Information Update: 29 May 2026
At a glance
- Originator Ichnos Sciences
- Developer Almirall S.A.
- Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Discontinued Autoimmune disorders
Most Recent Events
- 19 Mar 2026 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-experienced) in Ireland (SC) (CTIS2025-521293-34-00)
- 03 Feb 2026 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-experienced) in Germany (SC) (CTIS2025-521293-34-00)
- 02 Feb 2026 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-experienced) in Poland (SC) (CTIS2025-521293-34-00)